Long interfering nucleic acid duplexes targeting multiple RNA targets
Long interfering nucleic acid (iNA) duplexes, which are at least 30 nucleotides in length, which have at least one nick or nucleotide gap in the antisense or the sense strands or in both the sense and antisense strands. These long iNA duplexes do not induce an interferon response when transfected into mammalian cells. The antisense strands can target two separate mRNAs or two segments of one mRNA.
1. An interfering nucleic acid (iNA) duplex comprised of a sense strand of nucleotides having a 5′ end and a 3′ end annealed onto an antisense strand of nucleotides having a 5′ end and a 3′ end wherein the antisense strand has at least two segments, wherein one segment of the antisense strand can target a first RNA and another segment of the antisense strand can target a second RNA, or one segment of the antisense strand can target a first portion of an RNA and another segment of the antisense strand can target a second non-contiguous portion of said RNA, wherein the sense strand or the antisense strand or both are discontinuous, and wherein the iNA does not induce an interferon-response when transfected into a cell.
2. The iNA duplex of claim 1 , wherein there is a nick or gap between 2 nucleotides in the sense strand wherein said nucleotide gap in said sense strand is at least 1-20 nucleotides in length.
3. The iNA duplex of claim 2 , wherein there is a nucleotide modification on one or more of the nucleotides on the sense strand and wherein the nucleotide modification is either a pyrrolindol or a stilbene linked to a nucleotide.
4. The iNA duplex of claim 3 , wherein the pyrrolindol is pyrenylmethylpyrrolindol and the stilbene is trimethoxystilbene.
5. The iNA duplex of claim 1 , wherein there is a nick between 2 nucleotides in the antisense strand or a nucleotide gap in the antisense strand wherein said nucleotide gap in said antisense strand is at least 1-20 nucleotides in length.
6. The iNA duplex of claim 5 , wherein there is a nucleotide modification on one or more of the nucleotides on the antisense strand and wherein the nucleotide modification is either a pyrrolindol or a stilbene linked to a nucleotide.
7. The iNA duplex of claim 6 , wherein the pyrrolindol is pyrenylmethylpyrrolindol and the stilbene is trimethoxystilbene.
8. The iNA duplex of claim 1 , wherein the 3′ end of the sense strand is connected to the 5′ end of the antisense strand by means of a hairpin-loop of nucleotides.
9. The iNA duplex of claim 1 , wherein the iNA duplex is at least 30-80 nucleotides in length.
10. The iNA duplex of claim 1 , comprising a sense strand of nucleotides and two or more antisense strands annealed to the sense strand wherein there is at least one nucleotide gap or a nick between the antisense strands, and wherein the iNA duplex has a length of at least 30 nucleotides, and wherein each antisense strand a has 5′ and a 3′ end and the sense strand has a 5′ end and a 3′ end.
11. The iNA duplex of claim 10 , wherein each antisense strand targets a different mRNA or mRNA.
12. The iNA duplex of claim 10 , wherein each antisense strand targets different portions of an mRNA or miRNA.
13. The iNA duplex of claim 10 , wherein the 5′ end of the sense strand is connected to the 3′ end of the antisense strand by means of a hairpin-loop of nucleotides.
14. The iNA duplex of claim 10 , wherein the gap between the antisense strands is at least 1-20 nucleotides in length.
15. The iNA duplex of claim 10 , wherein each antisense strand is at least 15 nucleotides in length.
16. The iNA duplex of claim 10 , wherein there is a nucleotide gap or nick in the sense strand.
17. The iNA duplex of claim 1 , wherein the antisense strand is annealed to the sense strand, wherein there is at least one nick or one nucleotide gap in the antisense strand, and wherein the iNA duplex has a length of at least 30 nucleotides and wherein there is at least one nick or at least one nucleotide gap in the sense strand.
18. The iNA duplex of claim 1 , comprising two or more sense strands and two or more antisense strands wherein the antisense strands are annealed to the sense strands so as to produce one iNA duplex, and wherein said iNA duplex has a length of at least 30-80 nucleotides.
19. A pharmaceutical composition comprised of an iNA duplex having a sense strand of nucleotides having a 5′ end and a 3′ end annealed onto two or more antisense strands of nucleotides each strand having a 5′ end and a 3′ end wherein one antisense strand can target a first mRNA and one antisense strand can target a second mRNA, or one antisense strand can target one site on an mRNA and one antisense strand can target another non-contiguous site on said mRNA and wherein the iNA does not induce an interferon-response when transfected into a cell, and a pharmaceutically acceptable excipient.
20. The pharmaceutical composition of claim 19 , wherein the first mRNA encodes a ligand and the second mRNA encodes a receptor to said ligand.
21. A method of down-regulating an mRNA in a mammal comprising administering the pharmaceutical composition of claim 19 to the mammal.
22. The iNA duplex of claim 2 , wherein there is a nucleotide modification on one or more of the nucleotides on the sense strand and wherein the nucleotide modification is a pyrrolindol linked to a nucleotide.
23. The iNA duplex of claim 1 , comprising a sense strand of nucleotides and two antisense strands annealed to the sense strand wherein there is at least one nucleotide gap or a nick between the antisense strands, and wherein the iNA duplex has a length of at least 30 nucleotides, and wherein each antisense strand a has 5′ and a 3′ end and the sense strand has a 5′ end and a 3′ end.